KR20230121625A - 폴리뉴클레오타이드의 개선된 시험관내 조립을 위한조성물 및 방법 - Google Patents
폴리뉴클레오타이드의 개선된 시험관내 조립을 위한조성물 및 방법 Download PDFInfo
- Publication number
- KR20230121625A KR20230121625A KR1020237024116A KR20237024116A KR20230121625A KR 20230121625 A KR20230121625 A KR 20230121625A KR 1020237024116 A KR1020237024116 A KR 1020237024116A KR 20237024116 A KR20237024116 A KR 20237024116A KR 20230121625 A KR20230121625 A KR 20230121625A
- Authority
- KR
- South Korea
- Prior art keywords
- dna
- overhangs
- ligase
- fragments
- overhang
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 142
- 102000040430 polynucleotide Human genes 0.000 title claims description 131
- 108091033319 polynucleotide Proteins 0.000 title claims description 131
- 239000002157 polynucleotide Substances 0.000 title claims description 131
- 238000000338 in vitro Methods 0.000 title claims description 10
- 239000000203 mixture Substances 0.000 title abstract description 17
- 239000012634 fragment Substances 0.000 claims abstract description 329
- 102000003960 Ligases Human genes 0.000 claims abstract description 199
- 108090000364 Ligases Proteins 0.000 claims abstract description 199
- 238000006243 chemical reaction Methods 0.000 claims abstract description 107
- 108091008146 restriction endonucleases Proteins 0.000 claims abstract description 67
- 108091034117 Oligonucleotide Proteins 0.000 claims abstract description 60
- 238000003776 cleavage reaction Methods 0.000 claims abstract description 50
- 230000007017 scission Effects 0.000 claims abstract description 50
- 239000012190 activator Substances 0.000 claims abstract description 47
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 44
- 239000002773 nucleotide Substances 0.000 claims abstract description 43
- 230000003612 virological effect Effects 0.000 claims abstract description 23
- 230000001580 bacterial effect Effects 0.000 claims abstract description 12
- 108010061982 DNA Ligases Proteins 0.000 claims description 195
- 102000012410 DNA Ligases Human genes 0.000 claims description 195
- 108020004414 DNA Proteins 0.000 claims description 163
- 239000002202 Polyethylene glycol Substances 0.000 claims description 53
- 229920001223 polyethylene glycol Polymers 0.000 claims description 53
- 239000000758 substrate Substances 0.000 claims description 49
- 230000000295 complement effect Effects 0.000 claims description 47
- 102000004190 Enzymes Human genes 0.000 claims description 44
- 108090000790 Enzymes Proteins 0.000 claims description 44
- 108090000623 proteins and genes Proteins 0.000 claims description 36
- 241000701245 Paramecium bursaria Chlorella virus 1 Species 0.000 claims description 30
- 239000013612 plasmid Substances 0.000 claims description 28
- 238000013461 design Methods 0.000 claims description 26
- 230000000694 effects Effects 0.000 claims description 24
- 239000011541 reaction mixture Substances 0.000 claims description 24
- 108010042407 Endonucleases Proteins 0.000 claims description 22
- 238000003752 polymerase chain reaction Methods 0.000 claims description 21
- 210000004027 cell Anatomy 0.000 claims description 19
- 238000000137 annealing Methods 0.000 claims description 18
- 102000004169 proteins and genes Human genes 0.000 claims description 14
- 102000053602 DNA Human genes 0.000 claims description 13
- 102100031780 Endonuclease Human genes 0.000 claims description 11
- 238000004458 analytical method Methods 0.000 claims description 11
- 238000005304 joining Methods 0.000 claims description 11
- 230000002829 reductive effect Effects 0.000 claims description 11
- 150000003839 salts Chemical class 0.000 claims description 11
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 10
- 230000003321 amplification Effects 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 9
- 238000012360 testing method Methods 0.000 claims description 9
- 239000013598 vector Substances 0.000 claims description 9
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 8
- 230000037353 metabolic pathway Effects 0.000 claims description 8
- 230000002194 synthesizing effect Effects 0.000 claims description 8
- 102000011724 DNA Repair Enzymes Human genes 0.000 claims description 7
- 108010076525 DNA Repair Enzymes Proteins 0.000 claims description 7
- 230000027455 binding Effects 0.000 claims description 7
- 230000035772 mutation Effects 0.000 claims description 7
- 238000007702 DNA assembly Methods 0.000 claims description 6
- 239000000427 antigen Substances 0.000 claims description 6
- 108091007433 antigens Proteins 0.000 claims description 6
- 102000036639 antigens Human genes 0.000 claims description 6
- 230000029087 digestion Effects 0.000 claims description 6
- 238000003780 insertion Methods 0.000 claims description 6
- 230000037431 insertion Effects 0.000 claims description 6
- 210000004881 tumor cell Anatomy 0.000 claims description 6
- 229960005486 vaccine Drugs 0.000 claims description 6
- 230000003115 biocidal effect Effects 0.000 claims description 5
- 230000002255 enzymatic effect Effects 0.000 claims description 5
- 230000008439 repair process Effects 0.000 claims description 5
- 238000005382 thermal cycling Methods 0.000 claims description 5
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 210000000349 chromosome Anatomy 0.000 claims description 4
- 230000001351 cycling effect Effects 0.000 claims description 4
- 230000001419 dependent effect Effects 0.000 claims description 4
- 230000014509 gene expression Effects 0.000 claims description 4
- 108091033409 CRISPR Proteins 0.000 claims description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 2
- 210000002865 immune cell Anatomy 0.000 claims description 2
- 238000000126 in silico method Methods 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract description 13
- 239000000047 product Substances 0.000 description 62
- 239000000872 buffer Substances 0.000 description 32
- 150000007523 nucleic acids Chemical class 0.000 description 28
- 238000011534 incubation Methods 0.000 description 24
- 238000000429 assembly Methods 0.000 description 23
- 230000000712 assembly Effects 0.000 description 23
- 102000039446 nucleic acids Human genes 0.000 description 23
- 108020004707 nucleic acids Proteins 0.000 description 23
- 241000588724 Escherichia coli Species 0.000 description 17
- 238000003556 assay Methods 0.000 description 16
- 238000012163 sequencing technique Methods 0.000 description 16
- -1 i.e. Proteins 0.000 description 15
- 239000011159 matrix material Substances 0.000 description 13
- 239000013615 primer Substances 0.000 description 13
- 102000004533 Endonucleases Human genes 0.000 description 11
- 238000010367 cloning Methods 0.000 description 9
- 108091093088 Amplicon Proteins 0.000 description 8
- 241000700605 Viruses Species 0.000 description 8
- 238000003491 array Methods 0.000 description 8
- 239000003153 chemical reaction reagent Substances 0.000 description 8
- 238000004590 computer program Methods 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- JEOQACOXAOEPLX-WCCKRBBISA-N (2s)-2-amino-5-(diaminomethylideneamino)pentanoic acid;1,3-thiazolidine-4-carboxylic acid Chemical compound OC(=O)C1CSCN1.OC(=O)[C@@H](N)CCCN=C(N)N JEOQACOXAOEPLX-WCCKRBBISA-N 0.000 description 7
- VUFNLQXQSDUXKB-DOFZRALJSA-N 2-[4-[4-[bis(2-chloroethyl)amino]phenyl]butanoyloxy]ethyl (5z,8z,11z,14z)-icosa-5,8,11,14-tetraenoate Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)OCCOC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 VUFNLQXQSDUXKB-DOFZRALJSA-N 0.000 description 7
- 102100039217 3-ketoacyl-CoA thiolase, peroxisomal Human genes 0.000 description 7
- 101100153048 Homo sapiens ACAA1 gene Proteins 0.000 description 7
- 108091028043 Nucleic acid sequence Proteins 0.000 description 7
- 230000008901 benefit Effects 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- YRIZYWQGELRKNT-UHFFFAOYSA-N 1,3,5-trichloro-1,3,5-triazinane-2,4,6-trione Chemical compound ClN1C(=O)N(Cl)C(=O)N(Cl)C1=O YRIZYWQGELRKNT-UHFFFAOYSA-N 0.000 description 6
- FSNCEEGOMTYXKY-JTQLQIEISA-N Lycoperodine 1 Natural products N1C2=CC=CC=C2C2=C1CN[C@H](C(=O)O)C2 FSNCEEGOMTYXKY-JTQLQIEISA-N 0.000 description 6
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical group O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 239000011535 reaction buffer Substances 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 230000009466 transformation Effects 0.000 description 6
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 6
- 101000829958 Homo sapiens N-acetyllactosaminide beta-1,6-N-acetylglucosaminyl-transferase Proteins 0.000 description 5
- 102100023315 N-acetyllactosaminide beta-1,6-N-acetylglucosaminyl-transferase Human genes 0.000 description 5
- 102100030569 Nuclear receptor corepressor 2 Human genes 0.000 description 5
- 101710153660 Nuclear receptor corepressor 2 Proteins 0.000 description 5
- 238000004891 communication Methods 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 238000009396 hybridization Methods 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 230000008018 melting Effects 0.000 description 5
- 238000002844 melting Methods 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- 231100000331 toxic Toxicity 0.000 description 5
- 230000002588 toxic effect Effects 0.000 description 5
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 4
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- 241000701867 Enterobacteria phage T7 Species 0.000 description 4
- 108091092584 GDNA Proteins 0.000 description 4
- 239000008118 PEG 6000 Substances 0.000 description 4
- 229910019142 PO4 Inorganic materials 0.000 description 4
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 4
- WCDYMMVGBZNUGB-ORPFKJIMSA-N [(2r,3r,4s,5r,6r)-6-[[(1r,3r,4r,5r,6r)-4,5-dihydroxy-2,7-dioxabicyclo[4.2.0]octan-3-yl]oxy]-3,4,5-trihydroxyoxan-2-yl]methyl 3-hydroxy-2-tetradecyloctadecanoate Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](COC(=O)C(CCCCCCCCCCCCCC)C(O)CCCCCCCCCCCCCCC)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H]2OC[C@H]2O1 WCDYMMVGBZNUGB-ORPFKJIMSA-N 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 239000000470 constituent Substances 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 238000005580 one pot reaction Methods 0.000 description 4
- 238000005457 optimization Methods 0.000 description 4
- 230000036961 partial effect Effects 0.000 description 4
- 235000021317 phosphate Nutrition 0.000 description 4
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 101150075675 tatC gene Proteins 0.000 description 4
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical group CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 4
- 108010052418 (N-(2-((4-((2-((4-(9-acridinylamino)phenyl)amino)-2-oxoethyl)amino)-4-oxobutyl)amino)-1-(1H-imidazol-4-ylmethyl)-1-oxoethyl)-6-(((-2-aminoethyl)amino)methyl)-2-pyridinecarboxamidato) iron(1+) Proteins 0.000 description 3
- BCOSEZGCLGPUSL-UHFFFAOYSA-N 2,3,3-trichloroprop-2-enoyl chloride Chemical compound ClC(Cl)=C(Cl)C(Cl)=O BCOSEZGCLGPUSL-UHFFFAOYSA-N 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 3
- 241000711573 Coronaviridae Species 0.000 description 3
- 241000721047 Danaus plexippus Species 0.000 description 3
- 241001123946 Gaga Species 0.000 description 3
- 102100040004 Gamma-glutamylcyclotransferase Human genes 0.000 description 3
- 102100036263 Glutamyl-tRNA(Gln) amidotransferase subunit C, mitochondrial Human genes 0.000 description 3
- 101000927847 Homo sapiens DNA ligase 3 Proteins 0.000 description 3
- 101000886680 Homo sapiens Gamma-glutamylcyclotransferase Proteins 0.000 description 3
- 101001001786 Homo sapiens Glutamyl-tRNA(Gln) amidotransferase subunit C, mitochondrial Proteins 0.000 description 3
- 101001128634 Homo sapiens NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 2, mitochondrial Proteins 0.000 description 3
- 101000869690 Homo sapiens Protein S100-A8 Proteins 0.000 description 3
- 101000666730 Homo sapiens T-complex protein 1 subunit alpha Proteins 0.000 description 3
- 102100032194 NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 2, mitochondrial Human genes 0.000 description 3
- 101710163270 Nuclease Proteins 0.000 description 3
- 102100032442 Protein S100-A8 Human genes 0.000 description 3
- 102100038410 T-complex protein 1 subunit alpha Human genes 0.000 description 3
- 108010006785 Taq Polymerase Proteins 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 206010016256 fatigue Diseases 0.000 description 3
- 238000005755 formation reaction Methods 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 102000046719 human LIG3 Human genes 0.000 description 3
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 3
- CJWXCNXHAIFFMH-AVZHFPDBSA-N n-[(2s,3r,4s,5s,6r)-2-[(2r,3r,4s,5r)-2-acetamido-4,5,6-trihydroxy-1-oxohexan-3-yl]oxy-3,5-dihydroxy-6-methyloxan-4-yl]acetamide Chemical compound C[C@H]1O[C@@H](O[C@@H]([C@@H](O)[C@H](O)CO)[C@@H](NC(C)=O)C=O)[C@H](O)[C@@H](NC(C)=O)[C@@H]1O CJWXCNXHAIFFMH-AVZHFPDBSA-N 0.000 description 3
- 230000001537 neural effect Effects 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 239000000376 reactant Substances 0.000 description 3
- 230000037432 silent mutation Effects 0.000 description 3
- 125000006850 spacer group Chemical group 0.000 description 3
- 230000009897 systematic effect Effects 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 229940035893 uracil Drugs 0.000 description 3
- 238000010200 validation analysis Methods 0.000 description 3
- FMKJUUQOYOHLTF-OWOJBTEDSA-N (e)-4-azaniumylbut-2-enoate Chemical compound NC\C=C\C(O)=O FMKJUUQOYOHLTF-OWOJBTEDSA-N 0.000 description 2
- JKMPXGJJRMOELF-UHFFFAOYSA-N 1,3-thiazole-2,4,5-tricarboxylic acid Chemical compound OC(=O)C1=NC(C(O)=O)=C(C(O)=O)S1 JKMPXGJJRMOELF-UHFFFAOYSA-N 0.000 description 2
- JTTIOYHBNXDJOD-UHFFFAOYSA-N 2,4,6-triaminopyrimidine Chemical compound NC1=CC(N)=NC(N)=N1 JTTIOYHBNXDJOD-UHFFFAOYSA-N 0.000 description 2
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 2
- 102100039819 Actin, alpha cardiac muscle 1 Human genes 0.000 description 2
- 241000726103 Atta Species 0.000 description 2
- 244000063299 Bacillus subtilis Species 0.000 description 2
- 235000014469 Bacillus subtilis Nutrition 0.000 description 2
- 238000011357 CAR T-cell therapy Methods 0.000 description 2
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 description 2
- 108010008758 Chlorella virus DNA ligase Proteins 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 108010008286 DNA nucleotidylexotransferase Proteins 0.000 description 2
- 230000007018 DNA scission Effects 0.000 description 2
- 230000006820 DNA synthesis Effects 0.000 description 2
- 230000004568 DNA-binding Effects 0.000 description 2
- 102100029764 DNA-directed DNA/RNA polymerase mu Human genes 0.000 description 2
- 108010067770 Endopeptidase K Proteins 0.000 description 2
- 108060002716 Exonuclease Proteins 0.000 description 2
- OOFLZRMKTMLSMH-UHFFFAOYSA-N H4atta Chemical compound OC(=O)CN(CC(O)=O)CC1=CC=CC(C=2N=C(C=C(C=2)C=2C3=CC=CC=C3C=C3C=CC=CC3=2)C=2N=C(CN(CC(O)=O)CC(O)=O)C=CC=2)=N1 OOFLZRMKTMLSMH-UHFFFAOYSA-N 0.000 description 2
- 101000959247 Homo sapiens Actin, alpha cardiac muscle 1 Proteins 0.000 description 2
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 description 2
- 101000724418 Homo sapiens Neutral amino acid transporter B(0) Proteins 0.000 description 2
- 239000006137 Luria-Bertani broth Substances 0.000 description 2
- 102100028267 Neutral amino acid transporter B(0) Human genes 0.000 description 2
- 102000014076 Nucleotidyl transferase domains Human genes 0.000 description 2
- 108050003811 Nucleotidyl transferase domains Proteins 0.000 description 2
- 229920002562 Polyethylene Glycol 3350 Polymers 0.000 description 2
- 102100029812 Protein S100-A12 Human genes 0.000 description 2
- 101710110949 Protein S100-A12 Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 2
- 229960005091 chloramphenicol Drugs 0.000 description 2
- 230000005757 colony formation Effects 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000001976 enzyme digestion Methods 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 102000013165 exonuclease Human genes 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 210000001654 germ layer Anatomy 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000002032 lab-on-a-chip Methods 0.000 description 2
- 238000007169 ligase reaction Methods 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000007403 mPCR Methods 0.000 description 2
- UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical compound [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 description 2
- 235000011285 magnesium acetate Nutrition 0.000 description 2
- 239000011654 magnesium acetate Substances 0.000 description 2
- 229940069446 magnesium acetate Drugs 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 235000011056 potassium acetate Nutrition 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 238000010845 search algorithm Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229940113082 thymine Drugs 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- PIEPQKCYPFFYMG-UHFFFAOYSA-N tris acetate Chemical compound CC(O)=O.OCC(N)(CO)CO PIEPQKCYPFFYMG-UHFFFAOYSA-N 0.000 description 2
- BAAVRTJSLCSMNM-CMOCDZPBSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-4-carboxybutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]pentanedioic acid Chemical compound C([C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCC(O)=O)C(O)=O)C1=CC=C(O)C=C1 BAAVRTJSLCSMNM-CMOCDZPBSA-N 0.000 description 1
- JEPVUMTVFPQKQE-AAKCMJRZSA-N 2-[(1s,2s,3r,4s)-1,2,3,4,5-pentahydroxypentyl]-1,3-thiazolidine-4-carboxylic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C1NC(C(O)=O)CS1 JEPVUMTVFPQKQE-AAKCMJRZSA-N 0.000 description 1
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 1
- FVFVNNKYKYZTJU-UHFFFAOYSA-N 6-chloro-1,3,5-triazine-2,4-diamine Chemical compound NC1=NC(N)=NC(Cl)=N1 FVFVNNKYKYZTJU-UHFFFAOYSA-N 0.000 description 1
- PWJFNRJRHXWEPT-UHFFFAOYSA-N ADP ribose Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OCC(O)C(O)C(O)C=O)C(O)C1O PWJFNRJRHXWEPT-UHFFFAOYSA-N 0.000 description 1
- SRNWOUGRCWSEMX-KEOHHSTQSA-N ADP-beta-D-ribose Chemical group C([C@H]1O[C@H]([C@@H]([C@@H]1O)O)N1C=2N=CN=C(C=2N=C1)N)OP(O)(=O)OP(O)(=O)OC[C@H]1O[C@@H](O)[C@H](O)[C@@H]1O SRNWOUGRCWSEMX-KEOHHSTQSA-N 0.000 description 1
- 241000023308 Acca Species 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 102100022524 Alpha-1-antichymotrypsin Human genes 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 241001083841 Aquatica Species 0.000 description 1
- 101000651036 Arabidopsis thaliana Galactolipid galactosyltransferase SFR2, chloroplastic Proteins 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 101100263837 Bovine ephemeral fever virus (strain BB7721) beta gene Proteins 0.000 description 1
- 241001678559 COVID-19 virus Species 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 108010060248 DNA Ligase ATP Proteins 0.000 description 1
- 102000008158 DNA Ligase ATP Human genes 0.000 description 1
- 101710156804 DNA ligase A Proteins 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 230000008265 DNA repair mechanism Effects 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 101710180995 Endonuclease 1 Proteins 0.000 description 1
- 101100316840 Enterobacteria phage P4 Beta gene Proteins 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102100040870 Glycine amidinotransferase, mitochondrial Human genes 0.000 description 1
- 241000856850 Goose coronavirus Species 0.000 description 1
- 108020005004 Guide RNA Proteins 0.000 description 1
- 101000678026 Homo sapiens Alpha-1-antichymotrypsin Proteins 0.000 description 1
- 101000893303 Homo sapiens Glycine amidinotransferase, mitochondrial Proteins 0.000 description 1
- 101000856513 Homo sapiens Inactive N-acetyllactosaminide alpha-1,3-galactosyltransferase Proteins 0.000 description 1
- 101000804764 Homo sapiens Lymphotactin Proteins 0.000 description 1
- 101000957437 Homo sapiens Mitochondrial carnitine/acylcarnitine carrier protein Proteins 0.000 description 1
- 102100025509 Inactive N-acetyllactosaminide alpha-1,3-galactosyltransferase Human genes 0.000 description 1
- 101150090152 Lig1 gene Proteins 0.000 description 1
- 102100035304 Lymphotactin Human genes 0.000 description 1
- 102100038738 Mitochondrial carnitine/acylcarnitine carrier protein Human genes 0.000 description 1
- 229910003177 MnII Inorganic materials 0.000 description 1
- 108010006519 Molecular Chaperones Proteins 0.000 description 1
- 238000000342 Monte Carlo simulation Methods 0.000 description 1
- 101100155034 Mus musculus Ubap2 gene Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- BAWFJGJZGIEFAR-NNYOXOHSSA-O NAD(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-O 0.000 description 1
- 108091061960 Naked DNA Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 108091081548 Palindromic sequence Proteins 0.000 description 1
- 241001318097 Paucibacter Species 0.000 description 1
- 229920002582 Polyethylene Glycol 600 Polymers 0.000 description 1
- 101000619947 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) DNA repair polymerase Proteins 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 201000008754 Tenosynovial giant cell tumor Diseases 0.000 description 1
- 241000589499 Thermus thermophilus Species 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- YRKCREAYFQTBPV-UHFFFAOYSA-N acetylacetone Chemical compound CC(=O)CC(C)=O YRKCREAYFQTBPV-UHFFFAOYSA-N 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000011094 buffer selection Methods 0.000 description 1
- 238000004422 calculation algorithm Methods 0.000 description 1
- 238000005266 casting Methods 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 108091092356 cellular DNA Proteins 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 238000009643 clonogenic assay Methods 0.000 description 1
- 231100000096 clonogenic assay Toxicity 0.000 description 1
- 230000001427 coherent effect Effects 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 238000013523 data management Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 208000035647 diffuse type tenosynovial giant cell tumor Diseases 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000034431 double-strand break repair via homologous recombination Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 108010052305 exodeoxyribonuclease III Proteins 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 238000010448 genetic screening Methods 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 239000012212 insulator Substances 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 101150094164 lysY gene Proteins 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000013028 medium composition Substances 0.000 description 1
- 230000005055 memory storage Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 238000001668 nucleic acid synthesis Methods 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000007505 plaque formation Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000002096 quantum dot Substances 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 238000007480 sanger sequencing Methods 0.000 description 1
- 230000011218 segmentation Effects 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 208000002918 testicular germ cell tumor Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000012384 transportation and delivery Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 108010032276 tyrosyl-glutamyl-tyrosyl-glutamic acid Proteins 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
- C12N15/1031—Mutagenizing nucleic acids mutagenesis by gene assembly, e.g. assembly by oligonucleotide extension PCR
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
- G16B30/20—Sequence assembly
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Microbiology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Medical Informatics (AREA)
- Evolutionary Biology (AREA)
- Molecular Biology (AREA)
- Plant Pathology (AREA)
- Theoretical Computer Science (AREA)
- Bioinformatics & Computational Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063125530P | 2020-12-15 | 2020-12-15 | |
| US63/125,530 | 2020-12-15 | ||
| US202163213807P | 2021-06-23 | 2021-06-23 | |
| US202163213859P | 2021-06-23 | 2021-06-23 | |
| US63/213,859 | 2021-06-23 | ||
| US63/213,807 | 2021-06-23 | ||
| PCT/US2021/010063 WO2022132198A2 (en) | 2020-12-15 | 2021-12-15 | Compositions and methods for improved in vitro assembly of polynucleotides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20230121625A true KR20230121625A (ko) | 2023-08-18 |
Family
ID=80682842
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020237024116A Pending KR20230121625A (ko) | 2020-12-15 | 2021-12-15 | 폴리뉴클레오타이드의 개선된 시험관내 조립을 위한조성물 및 방법 |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP4263827A2 (https=) |
| JP (1) | JP2024500105A (https=) |
| KR (1) | KR20230121625A (https=) |
| WO (1) | WO2022132198A2 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12435332B2 (en) | 2018-10-19 | 2025-10-07 | New England Biolabs, Inc. | Ordered assembly of multiple DNA fragments |
| US12188011B2 (en) | 2018-10-19 | 2025-01-07 | New England Biolabs, Inc. | Compositions and methods for improved in vitro assembly of polynucleotides |
| WO2023001141A1 (en) * | 2021-07-23 | 2023-01-26 | Shanghai Zion Pharma Co. Limited | Kras g12d inhibitors and uses thereof |
| CN116004682B (zh) * | 2022-08-19 | 2026-01-16 | 中国人民解放军军事科学院军事医学研究院 | 一种快速无痕制备含长多聚腺嘌呤的mRNA的方法及应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5248600A (en) * | 1990-12-14 | 1993-09-28 | The University Of North Carolina At Chapel Hill | Method of cleaving DNA |
| JP4663988B2 (ja) | 2002-04-12 | 2011-04-06 | ニュー・イングランド・バイオラブズ・インコーポレイティッド | Ｄｎａ操作のための方法および組成物 |
| JP2013514758A (ja) * | 2008-12-23 | 2013-05-02 | ニユー・イングランド・バイオレイブス・インコーポレイテツド | 修飾ｄｎａを切断するための組成物、方法および関連する使用 |
| US20210383891A1 (en) * | 2018-10-19 | 2021-12-09 | New England Biolabs, Inc. | Improved Ordered Assembly of Multiple DNA Fragments |
| CN209999070U (zh) | 2019-03-14 | 2020-01-31 | 南京德朔实业有限公司 | 电动螺丝批 |
-
2021
- 2021-12-15 JP JP2023536435A patent/JP2024500105A/ja active Pending
- 2021-12-15 WO PCT/US2021/010063 patent/WO2022132198A2/en not_active Ceased
- 2021-12-15 KR KR1020237024116A patent/KR20230121625A/ko active Pending
- 2021-12-15 EP EP21857017.4A patent/EP4263827A2/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022132198A3 (en) | 2022-08-18 |
| JP2024500105A (ja) | 2024-01-04 |
| EP4263827A2 (en) | 2023-10-25 |
| WO2022132198A2 (en) | 2022-06-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Pryor et al. | Enabling one-pot Golden Gate assemblies of unprecedented complexity using data-optimized assembly design | |
| AU2022201907B2 (en) | Method for identification and enumeration of nucleic acid sequence, expression, copy, or dna methylation changes, using combined nuclease, ligase, polymerase, and sequencing reactions | |
| US12606867B2 (en) | Highly sensitive in vitro assays to define substrate preferences and sites of nucleic-acid binding, modifying, and cleaving agents | |
| KR20230121625A (ko) | 폴리뉴클레오타이드의 개선된 시험관내 조립을 위한조성물 및 방법 | |
| Van Dijk et al. | Library preparation methods for next-generation sequencing: tone down the bias | |
| Ma et al. | Error correction in gene synthesis technology | |
| WO2020081768A1 (en) | Improved ordered assembly of multiple dna fragments | |
| US20050026208A1 (en) | Amplification of DNA to produce single-stranded product of defined sequence and length | |
| US11371095B2 (en) | High-throughput method for characterizing the genome-wide activity of editing nucleases in vitro (Change-Seq) | |
| US20250137000A1 (en) | Methods of preferentially amplifying nucleic acid molecules | |
| CN110607356B (zh) | 一种基因组编辑检测方法、试剂盒及应用 | |
| Struhl | Subcloning of DNA fragments | |
| CN115667511A (zh) | 多核苷酸序列的按需合成 | |
| Bitinaite et al. | DNA cloning and engineering by uracil excision | |
| Reisinger et al. | Total synthesis of multi-kilobase DNA sequences from oligonucleotides | |
| CN108026525A (zh) | 多核苷酸组装的组合物和方法 | |
| JP2005536213A (ja) | ポリヌクレオチドの選択的組合せランダム化の方法 | |
| US12188011B2 (en) | Compositions and methods for improved in vitro assembly of polynucleotides | |
| Finney et al. | Molecular cloning of PCR products | |
| Kalva et al. | Gibson Deletion: a novel application of isothermal in vitro recombination | |
| US20250101482A1 (en) | Heteroduplex theromstable ligation assembly (htla) and/or cyclic heteroduplex thermostable ligation assembly (chtla) for generating double-stranded dna fragments with single-stranded sticky ends | |
| CN116848244A (zh) | 用于改进多核苷酸体外组装的组合物和方法 | |
| Vladimir et al. | Optimization of Golden Gate assembly through application of ligation sequence-dependent fidelity and bias profiling | |
| US20250297301A1 (en) | Single-stranded end preserving adaptors | |
| Uppuluri | CRISPR-Cas9 Mediated Methods for Targeted Genomic Analyses Using Long-Read Platforms |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20230714 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20241212 Comment text: Request for Examination of Application |